<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805415</url>
  </required_header>
  <id_info>
    <org_study_id>91271</org_study_id>
    <secondary_id>307300</secondary_id>
    <nct_id>NCT00805415</nct_id>
  </id_info>
  <brief_title>Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens</brief_title>
  <official_title>Multicenter, Open-label, Randomized, Comparative Study to Evaluate Ovulation Inhibition With Two 4-phasic Oral Contraceptive Regimens Containing Estradiol Valerate and Dienogest Applied Daily for Three Cycles to 200 Healthy Female Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the ovulation inhibition of two 4-phasic oral
      contraceptive regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a Hoogland score of 5-6 (luteinized unruptured follicle [LUF] or ovulation)</measure>
    <time_frame>Treatment cycles 2 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a Hoogland score of 5-6 (LUF or ovulation)</measure>
    <time_frame>Treatment cycles 2 or 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of endometrial thickness</measure>
    <time_frame>Treatment cycles 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visibility of cervical mucus</measure>
    <time_frame>Treatment cycles 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian activity (Hoogland score)</measure>
    <time_frame>Posttreatment cycle (only subjects from center 2)Treatment cycles 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of follicle size</measure>
    <time_frame>Treatment cycles 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of hormone levels (follicle-stimulating hormone [FSH], luteinizing hormone [LH], progesterone and estradiol)</measure>
    <time_frame>Treatment cycles 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Throughout whole study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical, surgical and medication history, concomitant medication, general physical and gynecological examination, cervical smear, pregnancy test, adverse events, safety laboratory determinations, cycle control, vital signs</measure>
    <time_frame>Various timepoint throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Ovulation Inhibition</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EV/DNG (Qlaira, BAY86-5027, SH T00658K)</intervention_name>
    <description>Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EV/DNG (SH T00658L)</intervention_name>
    <description>Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women willing to use non-hormonal methods of contraception

        Exclusion Criteria:

          -  Women with any contraindication for oral contraceptive use, for example but not
             limited to: presence or history of venous or arterial thrombotic / thrombembolic
             events, hypertension, presence or history of severe hepatic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dinox GmbH Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dinox B.V.</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>July 14, 2011</last_update_submitted>
  <last_update_submitted_qc>July 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Healthcare AG</organization>
  </responsible_party>
  <keyword>Oral Contraceptive</keyword>
  <keyword>Ovulation Inhibition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

